Knight Therapeutics Inc T.GUD

Revenue addition ...

[MrMugsy]

Exelon had annual revenues for 2020 of approximately 47 Million US dollars for Canada and Latin America.

Hahaha - love it.

And ... the Baby Boomers are going to drive the sales/need for this.

Looks like Exelon is a Rivastigmine and I'm guessing that ATE might consider an H2S combo with a Rivastigmine in the future.  This product shows manageable side-effects that include stomach pain and heartburn/indigestion.  H2S just might allow for the active ingredient to be reduced and in turn, a reduction in stomach pain (future potential).

The future could be our friend !!!  Exciting !!!

[peter75]

quote johnathon this is for your grandkids five years ago stock is a pig and John runs this as tax haven sell if it bumps up lousy stock Jonathan head injury is a concern

[MrMugsy]

Not sure where to begin ... If you want to see how slowly this progresses, refer to Goodman's old company and you wont be surprised by how long it takes. His goal is to better people's lives ... if you knew him, you'd understand that.  A general "tax haven" comment isn't even close. I would certainly listen to your head injury concerns if you had examples that

[Chianchin]

It is a 1997 old drug off patent, how long will it take for new leading edge drugs currently being developed to exitnct Exelon off the market? I can think of at least half dozen biotechs currenlty in late stage clinical trial for Alzheimer’s disease. I think GUD has blinked again as the future belongs to  CRISP biotect soon to arrive for many disease. Simply look at who won the covid

[wagyusteak]

The question is why now and why the future but not the past 14 years?? There is a reason why they called it BRANDED GENERIC in LATAM. It's like Cocacola. It's just a freaking sugar drink which anyone can create. Big companies can reverse engineering to get the fomula and create the same product. But no one dares to compete with them. Why? 

[MrMugsy]

It's also interesting that Alzheimer's hasn't seen anything new since 2003. We now have Biogen's Aducanumab but if you follow that drug, it's getting a lot of flack from FDA.  Some side-effects for Abucanumab is swelling in the brain (ARIA) and headaches.  It relieves syptoms but it does not reverse the disease. I perfer the side-effects from Rivastigmine (of which